2.765USD+10.60%Mkt Cap: 181.44M USDP/E: —Last update: 2026-05-26
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company's lead product candidate is belapectin (GR-MD-02), …
Industry Peers
Biotechnology110.61BUSDP/E 25.8
106.49BDKKP/E 20.5
66.47BUSDP/E 15.5
46.51BEURP/E 30.5
43.17BEURP/E 35.9
39.41BUSDP/E 74.0
32.84BUSD—
31.18BSEKP/E 46.1
Indicators:|
Key Statistics
Company
Market Cap181.44M USD
Enterprise Value289.76M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-30.84M USD
Revenue/Share—
Last Price2.765 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees9
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS3632252025
Valuation
P/E (Trailing)—
P/E (Forward)-1.50
PEG-36.15
EV/EBITDA—
EV/Revenue—
P/S—
P/B-1.25
EPS (TTM)-0.41
EPS (Forward)-1.68
52W Range
1.22026% of range7.130
52W High7.130 USD
52W Low1.220 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE24.44%
ROA-157.87%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-23.88M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-10.45%
Net Debt121.60M USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity-1.06
Current Ratio2.15
Quick Ratio1.93
Book Value/Sh-2.0110 USD
Cash/Share0.2140 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:6
Split DateMar 23, 2012
Analyst Consensus
Rating1.0 (Strong Buy)
Target (Mean)11.00 USD
Target Range11.00 USD – 11.00 USD
# Analysts1
Ownership
Shares Out.65.86M
Float47.18M
Insiders29.09%
Institutions21.17%
Short Interest
Short Ratio21.9d
Short % Float17.61%
Short % Out.11.22%
Shares Short7.39M
Short (prev mo.)6.80M
Technical
SMA 502.479 (+11.5%)
SMA 2003.879 (-28.7%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)327.73K
Avg Vol (10d)332.65K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—